Using machine learning to predict early recurrence in multiple myeloma patients
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06767254
This study is testing if using machine learning can help doctors predict which patients with multiple myeloma are at higher risk for early relapse after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna (other) |
| Locations | 4 sites (Meldola, Forlì-Cesena and 3 other locations) |
| Trial ID | NCT06767254 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance risk prediction for patients with multiple myeloma (MM) by utilizing machine learning techniques to analyze clinical, genomic, and imaging data. The goal is to develop models that can accurately predict patient responses to therapy and the likelihood of early disease relapse. By integrating various data sources, the study seeks to identify high-risk patients who may not be adequately recognized by current risk stratification methods. This approach addresses the unmet clinical need for better management of MM, particularly for those at risk of rapid disease progression.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years and older who have been diagnosed with active multiple myeloma.
Not a fit: Patients who do not have a diagnosis of multiple myeloma or are under 18 years of age will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and personalized treatment strategies for multiple myeloma patients.
How similar studies have performed: Other studies have shown promise in using machine learning for risk prediction in various cancers, indicating potential success for this novel approach in multiple myeloma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Signed Informed Consent form for study participation and personal data processing * Diagnosis of active multiple myeloma Exclusion Criteria: * None
Where this trial is running
Meldola, Forlì-Cesena and 3 other locations
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS — Meldola, Forlì-Cesena, Italy (NOT_YET_RECRUITING)
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (RECRUITING)
- ARNAS "G. Brotzu" di Cagliari — Cagliari, Italy (NOT_YET_RECRUITING)
- Azienda Ospedaliera Universitaria Federico II — Naples, Italy (NOT_YET_RECRUITING)
Study contacts
- Principal investigator: Elena Zamagni, MD, PhD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Elena Zamagni, MD, PhD
- Email: e.zamagni@unibo.it
- Phone: +39 051 214 3680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma